Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: August 13, 2022

Details for Patent: 7,858,594

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,858,594 protect, and when does it expire?

Patent 7,858,594 protects TYZEKA and is included in two NDAs.

This patent has eleven patent family members in seven countries.

Summary for Patent: 7,858,594
Title:Crystalline and amorphous forms of beta-L-2'-deoxythymidine
Abstract:Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2'-deoxythymidine can be used in the manufacture of other forms of beta-L-2'-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.
Inventor(s): Jonaitis; David (West Lafayette, IN), Storer; Richard (Kent, GB)
Assignee: Novartis Pharma AG (Basel, CH)
Application Number:12/505,839
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Use;

Drugs Protected by US Patent 7,858,594

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TYZEKA telbivudine SOLUTION;ORAL 022154-001 Apr 28, 2009 DISCN No No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS See Plans and Pricing
Novartis TYZEKA telbivudine TABLET;ORAL 022011-001 Oct 25, 2006 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,858,594

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003265396 See Plans and Pricing
China 100376593 See Plans and Pricing
China 1714098 See Plans and Pricing
European Patent Office 1534727 See Plans and Pricing
European Patent Office 2607370 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.